Concepedia

Hyun-Choel Chung

HC

Statistics

Publications

3

Citations

84

H-Index

3

Active since

2015

Affiliations

Yonsei University(Current)

Tel Aviv Sourasky Medical Center

Merck & Co., Inc., Rahway, NJ, USA (United States)

Seoul National University

Yale Cancer Center

Hyun-Choel Chung is an author at Yonsei University specializing in checkpoint inhibitor therapy, oncology, and gastrointestinal oncology.

Publications per year

2015–2018

3

Publications

3

Relationship between PD-L1 expression and clinical outcomes in patients with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in KEYNOTE-012.

Yung‐Jue Bang, Hyun-Choel Chung, Veena Shankaran et al. · Journal of Clinical Oncology · 2015 · 45 citations

, , +17

Correlation of gene expression signatures and clinical outcomes in patients with advanced gastric cancer treated with pembrolizumab (MK-3475).

Veena Shankaran, Kei Muro, Yung‐Jue Bang et al. · Journal of Clinical Oncology · 2015 · 26 citations

, , +17

JAVELIN Gastric 100: Phase 3 trial of avelumab (anti-PD-L1) maintenance therapy versus continuation of first-line chemotherapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC).

Markus Moehler, Min‐Hee Ryu, Keun‐Wook Lee et al. · Journal of Clinical Oncology · 2018 · 13 citations

, , +15

1–3 of 3